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Pasteurella multocida, and Histophilus somni. Pathogens were isolated from samples submitted to the 
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analysis. Original susceptibility testing of these isolates for ceftiofur, danofloxacin, enrofloxacin, 
florfenicol, oxytetracycline, spectinomycin, tilmicosin, and tulathromycin was performed using Clinical and 
Laboratory Standards Institute guidelines. Data were analyzed using a Bayesian approach to evaluate 
whether retreatment with antimicrobials of different mechanistic classes (bactericidal or bacteriostatic) 
increased the probability of resistant BRD pathogen isolation in calves. The posterior distribution we 
calculated suggests that an increased number of treatments is associated with a greater probability of 
isolates resistant to at least one antimicrobial. Furthermore, the frequency of resistant BRD bacterial 
isolates was greater with retreatment using antimicrobials of different mechanistic classes than 
retreatment with the same class. Specifically, treatment protocols using a bacteriostatic drug first 
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pathogen isolation. In particular, first treatment with tulathromycin (bacteriostatic) followed by ceftiofur 
(bactericidal) was associated with the highest probability of resistant M. haemolytica among all 
antimicrobial combinations. These observations suggest that consideration should be given to 
antimicrobial pharmacodynamics when selecting drugs for retreatment of BRD. However, prospective 
studies are needed to determine the clinical relevance to antimicrobial stewardship programs in livestock 
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Abstract
Although 90% of BRD relapses are reported to receive retreatment with a different class of
antimicrobial, studies examining the impact of antimicrobial selection (i.e. bactericidal or
bacteriostatic) on retreatment outcomes and the emergence of antimicrobial resistance
(AMR) are deficient in the published literature. This survey was conducted to determine the
association between antimicrobial class selection for treatment and retreatment of BRD
relapses on antimicrobial susceptibility of Mannheimia haemolytica, Pasteurella multocida,
and Histophilus somni. Pathogens were isolated from samples submitted to the Iowa State
University Veterinary Diagnostic Laboratory from January 2013 to December 2015. A total
of 781 isolates with corresponding animal case histories, including treatment protocols,
were included in the analysis. Original susceptibility testing of these isolates for ceftiofur,
danofloxacin, enrofloxacin, florfenicol, oxytetracycline, spectinomycin, tilmicosin, and tula-
thromycin was performed using Clinical and Laboratory Standards Institute guidelines. Data
were analyzed using a Bayesian approach to evaluate whether retreatment with antimicrobi-
als of different mechanistic classes (bactericidal or bacteriostatic) increased the probability
of resistant BRD pathogen isolation in calves. The posterior distribution we calculated sug-
gests that an increased number of treatments is associated with a greater probability of iso-
lates resistant to at least one antimicrobial. Furthermore, the frequency of resistant BRD
bacterial isolates was greater with retreatment using antimicrobials of different mechanistic
classes than retreatment with the same class. Specifically, treatment protocols using a bac-
teriostatic drug first followed by retreatment with a bactericidal drug were associated with a
higher frequency of resistant BRD pathogen isolation. In particular, first treatment with tula-
thromycin (bacteriostatic) followed by ceftiofur (bactericidal) was associated with the highest
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probability of resistant M. haemolytica among all antimicrobial combinations. These obser-
vations suggest that consideration should be given to antimicrobial pharmacodynamics
when selecting drugs for retreatment of BRD. However, prospective studies are needed to
determine the clinical relevance to antimicrobial stewardship programs in livestock produc-
tion systems.
Introduction
Bovine respiratory disease (BRD) is one of the most important diseases facing the beef cattle
industry [1]. Annual economic losses due to BRD are estimated to approach $1 billion in the
United States alone [1,2]. Treatment and control of BRD are currently predicated on adminis-
tration of antimicrobial therapy directed toward the primary bacterial pathogens Mannheimia
haemolytica, Pasteurella multocida, and Histophilus somni. Antimicrobial drugs are broadly
classified into two groups, namely those that inhibit growth of the organism (i.e., bacterio-
static) and those that kill the organism (i.e., bactericidal). The National Animal Health Moni-
toring System Feedlot 2011 study reported that 21.2 ± 2.0% (mean ± standard error, SE) of
cattle in feedlots were administered antimicrobials to control an expected outbreak of BRD,
and approximately 15% of feedlot cattle required a second antimicrobial treatment for the dis-
ease [3,4,5]. Although approximately 90% of cases with BRD relapse were reported to receive
retreatment with a different antimicrobial mechanistic class [5], studies examining the impact
of antimicrobial drug class on retreatment outcomes and the emergence of antimicrobial resis-
tance (AMR) are scarce in the published literature. Knowledge of the impact of antimicrobial
drug selection on AMR emergence is needed to develop judicious use guidelines that preserve
antimicrobial efficacy and advance antimicrobial stewardship.
Minimum inhibitory concentration (MIC) data obtained from samples submitted to veteri-
nary diagnostic laboratories (VDLs) reflect antimicrobial susceptibility and are commonly
used to describe AMR changes in livestock populations [6,7,8]. A retrospective study of M.
haemolytica, recovered from lung samples submitted to the Kansas State University VDL
between 2009 and 2011, reported a 7-fold increase in the number of isolates resistant to five or
more antimicrobials over a 3-year period [9]. However, the association between antimicrobial
treatment and the recovery of a resistant M. haemolytica isolate could not be evaluated because
individual animal treatment histories were not reported. Recently, our group reported an asso-
ciation between treatment history and antimicrobial sensitivity results from bacterial isolates
obtained from BRD cases submitted to the Iowa State University VDL (ISU-VDL) from 2013–
2015 [10]. Bacterial isolates from cattle that received antimicrobial treatment showed a higher
incidence of antimicrobial resistance than isolates from untreated cattle. Furthermore, the per-
centage of resistant isolates increased with the number of antimicrobial treatments. However,
the relationships between the antimicrobial drug class selected for initial treatment and retreat-
ment as well as the frequency of AMR pathogen isolation were not investigated.
It was revealed more than 50 years ago that an overall reduction in antimicrobial efficacy
occurs when antimicrobials that cause target organism death (i.e., bactericidal agents) are used
in combination with antimicrobials that only inhibit bacterial replication (i.e., bacteriostatic
agents). Bacteriostatic antimicrobials inhibit bacterial growth without killing the organism
(i.e., bacterial growth is arrested in the stationary phase). Bactericidal antimicrobial agents are
more active on actively multiplying bacteria, resulting in cell death. It is therefore hypothesized
that in case of bacteriostatic-bactericidal combination, the growth inhibition induced by a bac-
teriostatic agent may result in an overall reduction of efficacy (reduced growth and killing of
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bacteria) of the bactericidal agent [11,12]. The resulting drug antagonism is associated with
poorer clinical outcomes [13,14]. These findings suggest that the choice of antimicrobial drug
class (i.e., bactericidal or bacteriostatic) in cases of relapse and retreatment may be a critical
control point for mitigating AMR in beef production systems.
The objectives of this study were to use a Bayesian approach to 1) obtain the posterior dis-
tribution of the resistance patterns for the number of treatments (1, 2, 3, or 4+) administered
to cases submitted to the ISU-VDL; and 2) test the hypothesis that antimicrobial resistant BRD
pathogens are recovered more frequently from calves that received second-line treatment
from a different antimicrobial class than from calves that received second-line treatment from
the same antimicrobial class.
Materials and methods
Study design
This cross-sectional study used data collected from the electronic and paper laboratory records
of the ISU-VDL from January 1, 2013 to December 2, 2015, including the original documents,
which were used to extract the relevant antimicrobial treatment information. The data were
retrieved in 2016.
Settings
The 1,251 isolates available for analysis were submitted to the ISU-VDL by referring veterinari-
ans from 24 states. The majority of isolates were from Iowa (778), Minnesota (80), and South
Dakota (49). Most isolates were obtained from animals housed in feedlots (498), confinement
operations (268), or pastures (162). The demographic information from the sample submis-
sions is summarized in S1 and S2 Tables.
Cases and case isolates
Bacterial isolate data and the corresponding case history information were included in the
study upon meeting the following criteria: 1) the submitted samples were from a bovine field
case (research cases were excluded); 2) M. haemolytica, P. multocida, or H. somni were isolated
via routine culture; 3) the sample that yielded the isolate was from the lower respiratory tract
(lung, pleural surface, bronchoalveolar lavage fluid); 4) MIC testing results were available; 5)
the submission form stated a history of respiratory disease and/or evidence of pneumonia was
described in autopsy findings or upon histological evaluation of lung tissue; and 6) the submit-
ting veterinarian provided a treatment history that included either the generic or trade name
of the antimicrobials used in the treatment of the case prior to sample submission.
Study size
No a priori sample size was determined because the study was intended to be cross-sectional
and hypothesis-generating. Therefore, sample size was determined solely by the number of eli-
gible isolates available during the study period.
Variables and data sources
The outcome of interest was the Clinical and Laboratory Standards Institute (CLSI)-validated
interpretive category based on MIC.
Susceptibility testing was performed according to standard laboratory methods based on
CLSI recommendations [15]. Briefly, the selected culture was grown overnight and a broth
dilution was inoculated on a standard 96-well susceptibility plate (BOPO6F, Thermo Scientific,
Antimicrobial drug class selection for retreatment of bovine respiratory disease and antimicrobial resistance
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Oakwood Village, OH, USA) using an automated inoculation system (Sensititre AIM, Thermo
Scientific). Susceptibility plates were read using a manual system (Sensititre Vizion System,
Thermo Scientific) following 18–24 h incubation at 37˚C.
Not all antimicrobial compounds included on the standard susceptibility plate have CLSI-
validated interpretive breakpoints; therefore, only antimicrobials with CLSI-approved break-
points [2] for respiratory disease caused by M. haemolytica, P.multocida or H.somni were
included in this study (S3 Table). The antimicrobials included in this study were ceftiofur,
danofloxacin, enrofloxacin, florfenicol, oxytetracycline, spectinomycin, tilmicosin, and tula-
thromycin. Established CLSI-validated breakpoints are not available for tilmicosin against P.
multocida or tilmicosin and danofloxacin against H. somni in BRD; therefore, these antimicro-
bials were included in this study using the CLSI-validated breakpoints for M. haemolytica.
Treatment history was recorded in the paper submission forms by the referring veterinar-
ian. Information regarding the number of antimicrobial treatments, specific antimicrobials
used and non-antimicrobial treatments was manually extracted from these records by one
investigator (AS). Isolates from submissions that explicitly stated no usage of antimicrobial
drugs were assigned the treatment history classification of none (“0”). Isolates from cases in
which information regarding antimicrobial treatments was unclear (e.g., “many” or “every-
thing”) or not given were classified as “unknown.” Isolates from cases with treatment histories
indicating the use of four or more antimicrobials were classified as “4+.”
Trade names were converted to generic drug names to determine the antimicrobial drug
class (bacteriostatic or bactericidal) and the sequence of class administration for first- and sec-
ond-line treatments. Drug class was assigned based on the established in vitro pharmacody-
namics of the antimicrobial agent as summarized in Table 1.
Data on potential confounders or effect modifiers extracted from the submission form, includ-
ing breed, sex, facility type, clinical signs, necropsy findings, vaccination status, and weights, were
recorded (S1 and S2 Tables). Finalized case report information, such as microscopic evidence of
pneumonia, also was noted. Case information was classified as “unknown” if the information was
not supplied or unclear. After each eligible record was identified, the submission forms for each
case were individually reviewed by a single researcher (AS). Antimicrobial treatments were
grouped as -cidal or -static based on expected antimicrobial pharmacodynamics.
Variable transformations
Due to sparse data for cases receiving multiple treatments, we arbitrarily chose to group
together animals that received more than three treatments (4+). Animals with unknown treat-
ment histories were excluded from the analysis.
Table 1. Classification of antimicrobial drugs on the basis of antimicrobial activity.
Bactericidal Bacteriostatic
Ceftiofur Chlortetracycline
Danofloxacin Florfenicol
Enrofloxacin Gamithromycin
Penicillin Oxytetracycline
Spectinomycin
Sulfadimethoxine
Tildipirosin
Tilmicosin
Tulathromycin
Tylosin
https://doi.org/10.1371/journal.pone.0219104.t001
Antimicrobial drug class selection for retreatment of bovine respiratory disease and antimicrobial resistance
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For the subset of animals receiving just two treatments, we created two categorical variables.
One categorical variable grouped the data into two levels: “same” to designate animals that
received first- and second-line treatment from the same drug class (i.e., either bacteriostatic
and bacteriostatic or bactericidal and bactericidal) and “different” to designate animals that
received first- and second-line treatment from different drug classes (i.e., either bacteriostatic
followed by bactericidal or bactericidal followed by bacteriostatic). We also created a four-level
categorical variable to capture all possible combinations (4 levels: bacteriostatic followed by
bactericidal, bacteriostatic followed by bacteriostatic, bactericidal followed by bacteriostatic,
and bactericidal followed by bactericidal).
Statistical analysis
Initial analysis included descriptive statistics to illustrate the distribution of the number of
treatments cross tabulated with the number of antimicrobials of which the isolate was classified
as resistant. The number of missing values also was determined. We created heat maps to
show the pairwise interactions of antimicrobial treatment combinations associated with the
isolation of resistant M. haemolytica. This analysis was not conducted for P. multocida and H.
somni due to the smaller number of isolates for each treatment combination that were available
for analysis.
The approach for addressing our two objectives was to conduct a Bayesian analysis for iso-
lates of M. haemolytica, P. multocida, and H. somni using a finite mixture model based on a
zero-inflated beta-binomial model. The open source software R was used to conduct this anal-
ysis. For both objectives, we let yij represent the number of resistant organisms, where i repre-
sents the level of the explanatory variable treatment and j represents the organism. We assume
the observations are conditionally independent. We write the model as follows:
ðyijjgi;zij ¼ 1Þ � Binomialð18; giÞ
ðP ðyij ¼ 0jgi;zij ¼ 0Þ ¼ 1
where zij represents the category (i.e., antimicrobial drug class) and n = 18 represents the num-
ber of possible antimicrobials. Thus, the probability density function of yij is:
18
yij
 !
g
yij
i ð1   giÞ
18  yij
 !zij
ðIðyij ¼ 0ÞÞ
1  zij
we allow the category indicator, zij, to also be conditionally independent with the following
distributional assumption:
zijjpi � Bernouli ðpiÞ
Rho (pi) and gamma (γi) are assumed to be independent with priors specified as follows:
gi � Beta ða; bÞ
pi � Beta ða; bÞ
where a = 1 and b = 1.
For Objective 1, i in the model referred to the number of treatments reported by the sub-
mitter (i.e., i had five levels: 0, 1, 2, 3, and 4+ treatments). For Objective 2, two models were
created for the subset of animals that received two treatments. For the first model (Objective 2
Model 1), γi referred to the two-level sequence of treatments reported by the submitter (i.e., i
Antimicrobial drug class selection for retreatment of bovine respiratory disease and antimicrobial resistance
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had two levels: same and different). For the second model (Objective 2 Model 2), γi referred to
the four-level sequence of treatments reported by the submitter (i.e., i had four levels: bacteri-
cidal-bactericidal, bactericidal-bacteriostatic, bacteriostatic-bactericidal, and bacteriostatic-
bacteriostatic). We sampled from the joint posterior distribution of γi and ρi implied by the
model using a Metropolis random walk Markov chain Monte Carlo (MCMC) approach.
One output from each model was the posterior distribution of ρi based on each ith level of
the explanatory variable; i.e., ρi is the probability that an animal in group i comes from the
binomial distribution. We use this posterior distribution to make inferences about the data.
For example, we are interested in the probability that an organism is resistant to at least one
antimicrobial, which is given by ρi� (probability binomial [18, γi] random variable > 0). We
are also interested in whether this probability is associated with either the number of times an
animal is treated or the treatment sequence. The other output was the posterior distribution of
γi based on each ith level of the explanatory variable. Posterior γ distributions that are shifted to
the right indicate an isolate that is resistant to a higher number of antimicrobials.
To examine the relationship between the probability of at least one resistant test result and
the number of treatments, we determined the posterior distribution of pi+1> pi, i.e., how often
the probability of having at least one resistant test was higher for i + 1 treatments compared to
i treatments.
After creating the models, we assessed several discrepancy measures, including the number
of zeros in the posterior distribution of y� and the number of extreme values. This first reflects
the inflation of zeros in the observed distribution and is mainly informed by the posterior dis-
tribution of ρi. The second measure assesses the distribution of resistant organisms, given that
they are resistant, and is mainly informed by the posterior distribution of γi. For each posterior
distribution of γi and ρi, we reported the 95% credible interval (95% CI) and also the posterior
probability that γi < γ6¼i and ρi <ρ6¼i. for all possible pairwise comparisons.
Ancillary analyses and sensitivity analyses
We originally intended to conduct further subgroup analysis based on the particular isolates of
M. haemolytica, P. multocida, and H. somni. However, on further examination, we determined
that the data were too sparse to warrant further subgrouping. We also were originally inter-
ested in the impact of two covariates, simultaneous viral and Mycoplasma spp. infection, on
the posterior distribution; however, descriptive analysis indicated that this approach was
unlikely to be useful. Thus, although we extracted these data, we did not conduct these
analyses.
Results
A total of 1,251 bacterial isolates were available for our analysis, including 540 isolates of M.
haemolytica, 404 isolates of P. multocida, and 307 isolates of H. somni. Isolates were obtained
from 1,031 individual animals under 989 case submissions by 378 veterinarians. Table 2 sum-
marizes the numbers of each organism isolated each year over the course of the study.
The data set of 781 out of 1,251 bacterial isolates was used for analysis because 470 isolates
did not have treatment information included with the sample submission. The dataset avail-
able for Objective 1 included 781 isolates, of which 194 received 0 treatments, 276 received 1
treatment, 211 received 2 treatments, 74 received 3 treatments, 23 received 4 treatments, 2
received 5 treatments, and 1 received 7 treatments. Missing data for this subset are presented
in S1 Table. A total of 211 isolates were from animals that received only two treatments. These
isolates were treated with the same drug class in 97 cases (18 bactericidal-bactericidal and 79
Antimicrobial drug class selection for retreatment of bovine respiratory disease and antimicrobial resistance
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bacteriostatic-bacteriostatic) and 114 were treated with different drug classes (52 bactericidal-
bacteriostatic and 62 bacteriostatic-bactericidal).
The observed antimicrobial susceptibility profiles for M. haemolytica based on MIC data of
cattle administered either the “same” (first and second treatment were both either bactericidal
drugs, or bacteriostatic drugs) or “different” (first treatment was bactericidal and second was
bacteriostatic or vice versa) antimicrobial treatment are presented in Fig 1. A similar examina-
tion of the data was not conducted for P. multocida and H. somni because there were an insuf-
ficient number of isolates for this to be meaningful.
Antimicrobial treatments were grouped based on their anticipated impact on bacterial
growth in vitro, i.e., bactericidal (“cidal”) or bacteriostatic (“static”). We created a heat map to
illustrate the impact of specific pairs of combinations of first and second antimicrobial treat-
ments on the number of isolates identified as resistant against the listed antimicrobials with
CLSI breakpoints (Fig 2). Red indicates the observed maximum number of resistant isolates and
white (i.e., blank) represents no observation of antimicrobial resistance for a specific antimicro-
bial combination (Fig 2). A similar examination of the data was not conducted for P. multocida
and H. somni because there were an insufficient number of isolates for this to be meaningful.
The distribution of AMR in bacterial isolates demonstrated an association between the iso-
lation of an AMR bacteria and the number of treatments used (Fig 3 and Table 3). The data
indicate that administration of two or more antimicrobial agents to treat BRD in cattle may
increase the likelihood of isolating an antimicrobial resistant pathogen (Fig 3).
Table 2. Summary of bacterial isolates obtained from submitted samples of animals treated with bacteriostatic/bactericidal antimicrobial agents.
Year 2013 2014 2015 Total
Organisms (culture) MH PM HS MH PM HS MH PM HS
Isolates from submissions with treatment history 113 56 52 127 90 81 106 94 62 781
Total isolates/year 221 298 262
Isolates from non-treated cases 28 19 13 27 29 17 25 19 17 194
60 73 61
Isolates from first-line bactericidal treatment
Ampicillin 0 0 0 1 0 0 0 2 0 3
Ceftiofur 14 1 5 15 10 11 13 8 4 81
Danofloxacin 0 1 0 1 1 0 0 0 0 3
Enrofloxacin 12 5 6 10 9 11 13 14 5 85
Penicillin 2 2 0 0 0 0 2 2 1 9
Total 48 69 64 181
Isolates from first-line bacteriostatic treatment
Chlortetracycline 0 0 0 4 4 1 1 0 1 11
Florfenicol 6 6 7 8 7 9 16 8 8 75
Gamithromycin 2 1 0 9 6 2 5 1 2 28
Oxytetracycline 2 1 1 0 3 1 1 2 1 12
Sulfadimethoxine 2 2 0 0 0 1 1 0 0 6
Tetracycline 0 0 0 5 2 2 0 1 2 12
Tildipirosin 11 3 4 6 5 6 4 8 3 50
Tilmicosin 4 4 4 8 1 5 2 2 0 30
Tulathromycin 29 10 11 33 13 15 24 26 18 179
Tylosin 1 1 1 0 0 0 0 0 0 3
Total 113 156 137 406
(MH = M. haemolytica, PM = P. multocida, HS = H. somni).
https://doi.org/10.1371/journal.pone.0219104.t002
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Fig 1. Distribution of minimum inhibitory concentrations (MIC) of antimicrobial agents with CLSI approved
breakpoints for M. haemolytica in cattle receiving the same or different treatments. S = susceptible; I = intermediate;
R = resistant. For “same” treatments, the first and second treatments were either bactericidal drugs or bacteriostatic drugs.
For “different” treatments, the first treatment was bactericidal and second was bacteriostatic or vice versa.
https://doi.org/10.1371/journal.pone.0219104.g001
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Fig 2. Heat maps showing pairwise interactions of antimicrobial treatment combinations associated with the isolation of resistant M. haemolytica
organisms. The effect of treatment with ceftiofur (CEF), danofloxacin (DANO), enrofloxacin (ENRO), florfenicol (FLOR), gamithromycin (GAM),
oxytetracycline (OXY), penicillin (PEN), spectinomycin (SPEC), sulfadimethoxine (SULF), tetracycline (TET), tildipirosin (TILD), tilmicosin (TILM),
tulathromycin (TUL), and tylosin (TYL) as either first (X-axis) or second (Y-axis) treatment on the frequency of isolating M. haemolytica organisms resistant to
danofloxacin (A), enrofloxacin (B), florfenicol (C), spectinomycin (D), tilmicosin (E) and tulathromycin (F) was examined using CLSI interpretive criteria.
White indicates no observation of antimicrobial resistance with that specific combination.
https://doi.org/10.1371/journal.pone.0219104.g002
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For Objective 1, the posterior distribution for ρ (i.e., the probability of being resistant to at
least one antimicrobial) is provided in Fig 4.
The 95% CI for the ρ distribution is provided in Table 3. Based on the interpretation of the
posterior distributions, the use of antimicrobials was associated with an increased probability
of having at least one resistant outcome because the median and 95% CIs shift to the right
toward higher probabilities as the number of antimicrobial treatments increased. In addition,
there was evidence of an exposure response (i.e., increasing the number of treatments increases
the probability of at least one resistant test). The evidence for a response to increasing antimi-
crobial exposure can be found in Table 4.
As reported in Table 4, ρ increased as the number of reported treatments increased. For
example, 40%, 82%, 99%, and 100% of the time, ρ was higher if animals received more than 4
treatments when compared to ρ for 3 treatments, 2 treatments, 1 treatment, or 0 treatments,
respectively. When ρ values were entered into the Bernoulli distribution, they translated into a
higher prevalence of isolates with at least one resistant outcome.
The posterior distributions of γ (where γi = number of resistant tests for each isolate) are
shown in Fig 5 (95% CI in Table 5).
Fig 3. Observed frequency distribution of antimicrobial resistant isolates based on CLSI breakpoints for animals receiving
antimicrobials for BRD. 0 = no treatment, 1 = 1 treatment, 2 = 2 treatments, 3 = 3 treatments, 4 = 4 or more treatments, and
NA = missing information.
https://doi.org/10.1371/journal.pone.0219104.g003
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Consistent with the results for ρ, there was evidence that increased exposure to antimicrobi-
als resulted in a higher probability of an isolate being resistant to more than one antimicrobial
(Table 6). However, for the difference between 3 treatments and 4+ treatments, there was only
49% probability (50/50) of one being higher than the other, suggesting a possible threshold or
an imprecise estimate of the γi posterior distribution.
Objective 2 examined the development of resistance based on whether the antimicrobial
selected for the initial treatment and retreatment would be expected to kill the bacteria in vitro
(bactericidal) or inhibit the replication of the bacteria in vitro (bacteriostatic). As shown in Fig
6 and Table 3, the posterior distribution of ρ (i.e., the probability of the isolate being resistant
to at least one antimicrobial) when animals received drugs of the same or different mechanistic
classes do not appear to be associated with different distributions.
However, when examining the posterior distribution of γ (where γi = number of resistant
tests for an isolate), the posterior probability of γdifferent > γsame was 99% (Fig 7 and Table 5).
The results of the analysis from Objective 2 Model 1 suggest that the sequential administra-
tion of antimicrobial treatments with different effects on bacterial growth may be associated
with higher numbers of resistant isolates and elevated MIC outcomes. Objective 2 Model 2
explores whether the sequence of bactericidal and bacteriostatic treatments has an impact on
the probability of recovering a resistant BRD isolate. This analysis suggests that there is little
impact of the treatment scheme sequence on the probability of identifying an isolate that is
resistant to at least one antimicrobial (ρ). The specific posterior distributions and the 95% CI
of ρ are shown in Fig 8 and Table 3. Similarly, the posterior probability of an organism being
resistant to at least one antimicrobial is presented in Table 7.
As reported in Table 7, the probability of an organism being resistant to at least one antibi-
otic (ρ) was similar for the different treatment combinations. Specifically, in 62%, 81%, and
35% of cases, the probability of an organism being resistant to at least one antibiotic was higher
if animals received a bacteriostatic antimicrobial for first treatment followed by a bactericidal
antimicrobial for retreatment of BRD when compared to bacteriostatic-bacteriostatic, bacteri-
cidal-bacteriostatic, and bactericidal-bactericidal treatment, respectively.
With respect to the treatment, posterior gamma (γ) distributions shifted to the right in ani-
mals that received a first line bacteriostatic antimicrobial followed by retreatment with a
Table 3. 95% credible intervals (CIs) for the posterior distributions representing the probability of having at least
one resistance result to at least one of the assessed antimicrobials (i.e., ρ) based on CLSI breakpoints stratified by
the number of antimicrobials the animal received.
Objective, Model Percentile
Objective 1 Model 1: treatment frequency (n = 781) 2.5% 50% 97.5%
0 treatments 0.29 0.36 0.55
1 treatment 0.49 0.55 0.61
2 treatments 0.63 0.69 0.76
3 treatments 0.69 0.80 0.88
4+ treatments 0.61 0.78 0.90
Two treatment sequences (n = 211)
Same (bactericidal + bactericidal, bacteriostatic + bacteriostatic) 0.61 0.71 0.79
Different (bacteriostatic + bactericidal, bactericidal + bacteriostatic) 0.59 0.69 0.76
Four treatment sequences (n = 211)
Bactericidal + bactericidal 0.54 0.77 0.92
Bactericidal + bacteriostatic 0.51 0.64 0.76
Bacteriostatic + bacteriostatic 0.59 0.69 0.79
Bacteriostatic + bactericidal 0.60 0.72 0.82
https://doi.org/10.1371/journal.pone.0219104.t003
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bactericidal antimicrobial (Fig 9). This suggests that BRD pathogens isolated from these ani-
mals would be more likely to test resistant to more than one antimicrobial (Table 5). A higher
probability (>95%) of obtaining a resistant isolate from an animal receiving first-line bacterio-
static treatment followed by retreatment with a bactericidal antimicrobial than the other
sequences was obtained(Table 8).
Fig 4. Posterior distribution of the probability that the isolate is resistant to at least one antimicrobial (i.e.,ρ) stratified
by treatment frequency. 0 = no treatment, 1 = 1 treatment, 2 = 2 treatments, 3 = 3 treatments, and 4+ = 4 or more
treatments.
https://doi.org/10.1371/journal.pone.0219104.g004
Table 4. Posterior probability that the posterior distribution of pi+1> pi.
Objective 1 Model 1 0 treatments 1 treatment 2 treatments 3 treatments 4+ treatments
0 treatments NA 0.99 1 1 1
1 treatment - NA 0.99 1 0.99
2 treatments - NA 0.95 0.82
3 treatments - - NA 0.40
4+ treatments - - - NA
i represents the number of treatment approaches that differ based on Objective 1 Model 1.
https://doi.org/10.1371/journal.pone.0219104.t004
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Discussion
In North America, BRD in feedlot cattle is associated with substantial economic losses due to
the cost of treatment and deleterious effects on animal health and production [1–5]. Although
BRD has a complex, multifactorial etiology, M. haemolytica, P. multocida, and H. somni are
most often associated with clinical disease [16]. Therefore, use of antimicrobials is essential for
the control and treatment of BRD in cattle [16]. Commonly used antimicrobial drugs that are
approved in the US for treatment of BRD include ceftiofur, tilmicosin, tulathromycin, florfeni-
col, enrofloxacin, and danofloxacin [16]. In recent years, an increasing number of reports
regarding the emergence of antimicrobial resistance among common BRD pathogens has
been published [9, 17–23]. Typically, cattle affected with BRD are treated with a drug of a dif-
ferent antimicrobial class than the drug administered for first treatment or for disease preven-
tion (metaphylaxis) [5]. Furthermore, when an animal does not respond to the first-line
antimicrobial treatment or metaphylaxis, it may be retreated with one or more additional clas-
ses of antimicrobial drugs over subsequent days [16].
Fig 5. Posterior distributions of the probability that the isolate is resistant to multiple antimicrobials (i.e., γi) stratified
by treatment frequency. 0 = no treatment, 1 = 1 treatment, 2 = 2 treatments, 3 = 3 treatments, and 4+ = 4 or more
treatments.
https://doi.org/10.1371/journal.pone.0219104.g005
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Data analyzed in the present study confirm that multiple antimicrobial classes are used to
treat BRD (Table 2). In general, these antimicrobials either inhibit bacterial replication pri-
marily through disruption of protein synthesis, or they cause bacterial death by inhibiting cell
wall synthesis or disrupting DNA replication [16]. Regardless of the mechanism of action, anti-
microbials exert a selection pressure on bacterial populations that may result in the emergence
of antimicrobial resistant organisms. Specific factors that may contribute to resistance selec-
tion is the presence of antimicrobial concentrations that are below the MIC for the bacteria
[24,25]. Bacterial pre-exposure to antimicrobials has also been implicated as a risk factor for
AMR evolution during subsequent antimicrobial treatments [26–28]. Although previous labo-
ratory studies have identified multidrug resistant (MDR) isolates from lung tissues collected
from fatal BRD cases, antimicrobial resistance is not the only cause of death due to BRD
[9,17,22,23]. Other factors such as stress, the timing of antimicrobial administration relative to
the onset of the disease, a compromised host immune response, failure to achieve therapeutic
drug concentrations at the site of infection, management factors such as poor nutrition, vacci-
nation status or pre-existing or concurrent disease may also result in case fatalities.
Recently, the effect of sequential antimicrobial treatments on the development of antimi-
crobial resistance has been demonstrated for Pseudomonas aeruginosa and Klebsiella pneumo-
nia in vitro [28,29]. In these laboratory studies the emergence of antimicrobial resistance also
Table 5. Credibility percentiles for posterior distributions for the number of resistant test results from an isolate
(γi).
Percentile
Objective 1 Model 1: Treatment frequency 2.5% 50% 97.5%
0 treatments 0.09 0.11 0.13
1 treatment 0.17 0.19 0.21
2 treatments 0.21 0.23 0.25
3 treatments 0.23 0.26 0.28
4+ treatments 0.21 0.25 0.30
Objective 2 Model 1: 2-treatment sequences
Same (bactericidal + bactericidal, bacteriostatic + bacteriostatic) 0.18 0.20 0.23
Different (bacteriostatic + bactericidal, bactericidal + bacteriostatic) 0.23 0.25 0.28
Objective 2 Model 2: 4-treatment sequences
Bactericidal + bactericidal, 0.18 0.23 0.29
Bactericidal + bacteriostatic, 0.17 0.21 0.24
Bacteriostatic + bacteriostatic, 0.17 0.19 0.22
Bacteriostatic + bactericidal 0.26 0.28 0.32
https://doi.org/10.1371/journal.pone.0219104.t005
Table 6. Posterior probability that γi+1 is greater than γi where i is the number of treatment approaches which differ based on objective 1 model 1 and γi = number
of resistant tests for an isolate.
Objective 1 Model 1: Posterior distribution based on treatment frequency
i 0 treatments 1 treatments 2 treatments 3 treatments 4+ treatments
0 treatments NA 1 1 1 1
1 treatment - NA 0.99 1 0.99
2 treatments - NA 0.95 0.87
3 treatments - - NA 0.49
4+ treatments - - - NA
i is the number of treatments administered based on Objective 1 Model 1.
https://doi.org/10.1371/journal.pone.0219104.t006
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varied with the classes and concentrations of antimicrobials used for pre-exposure and sequen-
tial treatments. However, despite the frequent use of sequential treatments for the treatment of
BRD in cattle, there are no data investigating if certain drug classes, doses, or drug regimens
may promote, or minimize, the emergence of AMR when used sequentially.
To our knowledge, this survey is the first report that specifically considers AMR in livestock
in the context of retreatments by different classes of antimicrobials (i.e., bacteriostatic and bac-
tericidal) as well as different individual drugs (e.g., tulathromycin versus ceftiofur). Macro-
lides, such as tulathromycin and tildipirosin, are appealing as first-line treatments for the
control of BRD (metaphylaxis) in high risk cattle due to their efficacy and long residence times
in plasma and lung tissues. However, metaphylactic treatment with tulathromycin has been
associated with a higher prevalence of multidrug resistant M. haemolytica shedding in cattle
Fig 6. Posterior distribution of the probability that the isolate is resistant to at least one antimicrobial (i.e., ρi)
stratified by the expected in vitro activity (i.e. bactericidal or bacteriostatic) of first and second treatment. Same = same
in vitro effect on bacterial growth, i.e., bactericidal followed by bactericidal or bacteriostatic followed by bacteriostatic; or
different = different in vitro effect on bacterial growth, i.e., bactericidal followed by bacteriostatic or bacteriostatic followed
by bactericidal.
https://doi.org/10.1371/journal.pone.0219104.g006
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[17,30]. One explanation for the elevated antimicrobial resistance of M. haemolytica and P.
multocida is the persistence of macrolides at concentrations that are below the MIC for the tar-
get organism [24,25,31]. During minimal inter-treatment intervals of 3–5 days, macrolides
may still be present at biologically active concentrations that could allow for drug-drug inter-
actions to occur when a second antimicrobial treatment is administered. Therefore, longer
inter-treatment intervals are recommended when using antimicrobials with longer elimination
half-lives [16]. Unfortunately the interval between treatments was not recorded on the submis-
sion histories analyzed for the present study, so the impact of post-treatment interval on the
emergence of AMR could not be assessed. Even so, this report provides insights into potential
critical control points for antimicrobial stewardship in livestock production systems.
The exploratory data presented in this report suggest that treatment protocols involving
metaphylaxis, or first-line treatment, with a bacteriostatic antimicrobial followed by
Fig 7. Posterior distributions of the probability that the isolate is resistant to multiple antimicrobials (i.e., γi)
stratified by the expected in vitro activity (i.e. bactericidal or bacteriostatic) of first and second treatment.
Same = same in vitro effect on bacterial growth, i.e., bactericidal followed by bactericidal or bacteriostatic followed by
bacteriostatic or different = different in vitro effect on bacterial growth, i.e., bactericidal followed by bacteriostatic or
bacteriostatic followed by bactericidal.
https://doi.org/10.1371/journal.pone.0219104.g007
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retreatment with a bactericidal antimicrobial may be associated with an increased frequency of
resistant BRD pathogen isolation. This observation may be due to the fact that bacteriostatic
activity may antagonize the effect of bactericidal drugs. Specifically, bactericidal drugs act on
bacteria that are in a growth phase; thus, the inhibitory activity of a bacteriostatic drug on the
replication of bacteria may result in diminished activity of a subsequent bactericidal treatment
[11].
Fig 8. Posterior distribution of the probability that the isolate is resistant to at least one antimicrobial (i.e., ρi)
stratified by the expected in vitro activity (i.e. bactericidal or bacteriostatic) of first and second treatment. Cidal-
Cidal = bactericidal first treatment followed by bactericidal retreatment; Cidal-Static = bactericidal first treatment followed
by bacteriostatic retreatment; Static-Static = bacteriostatic first treatment followed by bacteriostatic retreatment; and Static-
Cidal = bacteriostatic first treatment followed by bactericidal retreatment.
https://doi.org/10.1371/journal.pone.0219104.g008
Table 7. Posterior probability that pi+1 is greater than pi (i -4-level treatment mechanism sequence for objective 2 model 2).
Bactericidal + bactericidal Bactericidal + bacteriostatic Bacteriostatic + bacteriostatic Bacteriostatic + bactericidal
Bactericidal + bactericidal NA 0.16 0.28 0.35
Bactericidal + bacteriostatic – NA 0.73 0.81
Bacteriostatic + bacteriostatic - - NA 0.62
Bacteriostatic + bactericidal - - - NA
i is the 4-level treatment scheme sequence for Objective 2 Model 2.
https://doi.org/10.1371/journal.pone.0219104.t007
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It is noteworthy that the classification of antimicrobials as bactericidal and bacteriostatic is
based on the concentration required to sterilize bacterial cultures in vitro. As such, this system
of classification may not be absolute for every combination of antimicrobial and bacterial iso-
late. For example, it has been reported in previous in vitro and ex vivo pharmacodynamics
studies conducted against pneumonia pathogens of pigs and cattle that oxytetracycline and
florfenicol may have bactericidal as opposed to bacteriostatic activity under certain conditions
Fig 9. Posterior distributions of the probability that the isolate is resistant to multiple antimicrobials (i.e., γi) stratified
by the expected in vitro activity (i.e. bactericidal or bacteriostatic) of first and second treatment. Cidal-Cidal = bactericidal
first treatment followed by bactericidal retreatment; Cidal-Static = bactericidal first treatment followed by bacteriostatic
retreatment; Static-Static = bacteriostatic first treatment followed by bacteriostatic retreatment; and Static-
Cidal = bacteriostatic first treatment followed by bactericidal retreatment.
https://doi.org/10.1371/journal.pone.0219104.g009
Table 8. Posterior probability that the γi is greater γi-1 (i -4-level treatment mechanism sequence for objective 2 model 2) where γi = number of resistant tests for an
isolate.
Objective 2 Model 2: Posterior distribution of 2-treatment sequence
bactericidal + bactericidal bactericidal + bacteriostatic bacteriostatic + bacteriostatic bacteriostatic + bactericidal
bactericidal + bactericidal NA 0.2 0.11 0.95
bactericidal + bacteriostatic - NA 0.32 0.99
bacteriostatic + bacteriostatic - - NA 1
bacteriostatic + bactericidal - - - NA
i is the 4-level treatment mechanism sequence for Objective 2 Model 2.
https://doi.org/10.1371/journal.pone.0219104.t008
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[32,33]. However, despite a few exceptions, broad mechanisms of action, such as protein syn-
thesis inhibition and impacts on the growth of the bacterial cell wall, tend to be conserved
within these mechanistic classes. Therefore, this classification serves as a useful guideline for
clinicians in broadly consider the pharmacodynamics of the antimicrobial and to determine
when two drugs may show synergistic or antagonistic interactions when used in combination
[12].
Our data suggest that the number of treatments as well as alternating antimicrobial drug
classes may impact antimicrobial resistance patterns. Damas et al. used three bactericidal anti-
microbial classes (penicillins, cephalosporins, and fluoroquinolones) to treat serious infections
in intensive care unit patients for 8-month periods over a 2-year study duration. After studying
the effect of the sequential use of these three antimicrobial classes, antimicrobial rotation was
associated with a higher risk for the development of antimicrobial resistance [34]. Similarly, in
our study, potential for selection of antibiotic-resistant bacteria increased when more treat-
ments were administered and when treatment exposure changed from one class to another
antimicrobial class.
Specifically, the heat map (Fig 2) highlights how various antimicrobial combinations may
influence the frequency of isolation of resistant M. haemolytica. For example, the combination
of the bacteriostatic antimicrobial, tulathromycin, as the first-line treatment and the bacteri-
cidal antimicrobial, ceftiofur, as the second-line treatment increased the number of bacterial
isolates that were resistant to danofloxacin (Fig 2A), enrofloxacin (Fig 2B), florfenicol (Fig 2C),
spectinomycin (Fig 2D), tilmicosin (Fig 2E) and tulathromycin (Fig 2F). The use of tildipirosin
as the first-line treatment and ceftiofur as the second-line treatment was also associated with
an increased frequency of isolation of resistant M. haemolytica, specifically for florfenicol. This
is not unexpected, given that tulathromycin and tildipirosin are in the same class of antimicro-
bials and have a similar mechanism of action. As previously mentioned, one explanation for
this observation is that bactericidal antimicrobials, such as ceftiofur, that inhibit cell wall syn-
thesis, are most effective against rapidly dividing bacteria. Previous exposure to bacteriostatic
antimicrobials, such as tulathromycin, that inhibit bacterial replication may therefore reduce
the number of actively dividing bacteria that are susceptible to the effects of ceftiofur resulting
in drug antagonism.
Although class-switching is one potential explanation for this observation, the increase in
the number of resistant isolates could also be attributed to this treatment combination being
associated with drugs that are typically formulated with long durations of activity. These for-
mulations may therefore represent a more significant selection pressure for resistant bacteria.
However, the use of ceftiofur as the first-line treatment and tulathromycin as the second-line
treatment resulted in recovery of fewer resistant M. haemolytica isolates. This observation sug-
gests that the sequence of antimicrobial drug treatments, and not the duration of antimicrobial
activity, contributed to the frequency of isolation of a resistant organism.
Differences between antimicrobial resistance patterns were examined by evaluating the
MIC distributions of M. haemolytica for ceftiofur, danofloxacin, enrofloxacin, florfenicol,
spectinomycin, tetracycline, tilmicosin, and tulathromycin (Fig 1). With the exception of cef-
tiofur and florfenicol, the number of resistant M. haemolytica isolates was greater when differ-
ent antimicrobial classes were used for the first and second treatments. However, the number
of susceptible M. haemolytica isolates did not differ with treatment drug class. In general, resis-
tance to ceftiofur was rare, even in isolates obtained from animals treated with different anti-
microbial classes. However, it is speculated that CLSI-approved breakpoints may not be
accurate for ceftiofur against M. haemolytica and P. multocida for treatment of respiratory dis-
ease. It is believed that exposure to antimicrobials offers an advantage to resistant mutants in
competition with the susceptible wild-type population [11]. However, the impact of multidrug
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combinations of different classes on positive selection of resistant mutants has not been closely
examined. In a previous report, authors described a change in the ratio of doxycycline-resis-
tant and doxycycline-sensitive E. coli following treatment with doxycycline alone or in combi-
nation with erythromycin [14]. The doxycycline-resistant mutants outnumbered the
susceptible wild-type population of E.coli in both treatment conditions, but there was greater
selection for the resistant mutants with the combination treatment. Van Loon et al. also
reported that bacteria exhibit reduced susceptibility during treatment when different classes of
antimicrobials were used [35].The results of the present survey are consistent with these
reports given that they suggests that using a combination of different classes of antimicrobials
may increase the risk of selection of resistant mutants.
Our ability to assess the impact of different drug classes on AMR for P. multocida and H.
somni was limited in the present study due to the relatively small number of isolates with asso-
ciated treatment histories that were available for analysis. It is known that the MIC distribution
for P. multocida and H. somni may not have the same pattern as M. haemolytica isolates. In a
previous report, pre-exposure to tulathromycin was associated with the development of bacte-
rial resistance in M. haemolytica but not in P. multocida [36]. The number of M. haemolytica
isolates compared to the number of P. multocida and H. somni isolates may influence the
observations of this study. Although use of different mechanistic classes of antimicrobials was
found to be associated with an increased frequency of isolation of resistant BRD pathogens,
the relatively small number of P. multocida and H. somni isolates that were present in this data-
set suggests that further investigation that specifically target these populations are needed
before definitive and overarching conclusions can be made.
Although antimicrobial resistance has been a concern of scientists for decades, and specific
BRD pathogen resistance was first reported over 40 years ago [37], our study appears to be the
first investigation of the effects of treatment frequency and drug class selection on subsequent
isolation of AMR organisms in cattle with BRD. The majority of published investigations have
focused on the impact of exposure to a single class of antimicrobial on the emergence of anti-
microbial resistance in feedlot cattle [17,21,30,38]. However, Kanwar and others reported that
oral administration of chlortetracycline (CTC) in feed after treatment with ceftiofur crystalline
free acid (CCFA) injection increased the recovery of ceftiofur-resistant bacteria from the feces
of feedlot cattle [39]. Although this study suggested that a combination of bactericidal (CCFA)
and bacteriostatic (CTC) antimicrobials may increase the risk of isolating AMR bacteria, they
did not attempt to investigate the impact of treatment sequence or multiple antimicrobial clas-
ses on antimicrobial resistance outcomes.
One of the challenges with this study, and similar datasets [7, 9, 10], is that samples submit-
ted to veterinary diagnostic laboratories may represent an inherently biased population of
non-responding BRD cases that may not represent the population at large. As such, respond-
ing cattle are essentially excluded from the analysis. Furthermore, these retrospective studies
assume that the treatment history and treatment sequence provided by the referring veterinar-
ian is accurate. As such, concurrent use of oral antimicrobials in feed, for example, may not
have been disclosed on the submission form and could potentially have increased the risk of
selection of AMR organisms [39]. A further limitation is that data regarding certain antimicro-
bial combinations were sparse while others were more abundant. Specifically, the data were
assembled before many of the recently approved long-acting antimicrobials for BRD, such as
tildipirosin and gamithromycin, were in common use. Despite these limitations, the current
study is hypothesis-generating and provides a novel approach for analyzing AMR microbes
from BRD cases where multiple treatments with antimicrobial classes are evaluated.
The impact of multiple antimicrobial treatments represents an understudied area of
research in veterinary medicine. It has been reported that feedlot cattle are commonly treated
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with antimicrobials more than once if the initial response is inadequate and that cattle that
receive multiple antimicrobial treatments exhibit higher mortality rates from disease [5, 10].
Furthermore, animals that fail to respond to the initial treatment with one class of drug (e.g.,
bacteriostatic) are usually retreated with a different class of drug (e.g., bactericidal), which sug-
gests a lack of consensus on any particular retreatment protocol [5, 16]. This lack of consensus
is likely due to the scarcity of literature on pathogen response to multiple treatment regimens
with different classes of antimicrobial agents. Our study suggests that sequential treatment
with different classes of antimicrobials may be a risk factor for developing drug resistance.
Therefore, a review of antimicrobial pre-exposure should be taken before the initiation of sub-
sequent antimicrobial therapy to assist with mitigating the emergence of antimicrobial resis-
tance in cattle infected with BRD.
As concern about the impact of AMR microbes on animal and public health increases, addi-
tional knowledge from studies such as the present survey is needed to investigate interventions
that could potentially reduce the development of antimicrobial resistance. Furthermore, a
microbiological diagnosis may be beneficial to assist with treatment selection for BRD of
unknown etiology. Unfortunately, the time it takes to obtain AMR isolate results and the asso-
ciated costs are two major limitations for the use of laboratory microbiology in veterinary
medicine [40]. Furthermore, this study demonstrates the value and importance of including
comprehensive treatment histories to accompany the submission of veterinary diagnostic labo-
ratory samples. Taken together, studies of antimicrobial sensitivity patterns can serve as a
guide to assist veterinarians in developing and implementing effective antimicrobial steward-
ship programs and protocols. Future studies on the relationship between treatment and anti-
microbial resistance could assist practitioners in making decisions regarding antimicrobial
retreatments when cattle exhibit BRD relapses.
These exploratory data suggest that treatment protocols stipulating first-line treatment with
a bacteriostatic followed by second-line treatment with a bactericidal may increase the proba-
bility of emergence of drug resistance. As concern about antimicrobial resistance increases
from an animal and public health perspective, this knowledge suggests potential ways to
reduce the development of resistance. The hypothesis that the impact of an antimicrobial on
bacterial growth may be associated with the risk of increased resistance needs to be tested in a
clinical trial. Such a trial would also need to determine whether treatment efficacy is affected
by a change in treatment protocol or post-treatment interval. If treatment effectiveness proves
to be the same, then we may have an avenue by which to reduce the induction of resistance via
the recommendation that veterinarians tailor their treatment regimens to reduce the potential
for AMR development.
Although this study is hypothesis-generating, it has several strengths. The data set is reason-
ably large for the questions we asked. Although a great deal of data was missing, we limited
our analysis to specific questions to avoid impact due to this missing data. Furthermore, we
recognized the limits of the passively collected and hypothesis-generating nature of the data by
not formally testing a hypothesis. The zero-inflated beta-binomial model that we used is an
intuitive model that fit the underlying data well. We could not adjust this model for any con-
founders because of missing data; however, given the cross-sectional nature of the data, any
attempt to adjust for confounders to improve causal inference would have been misleading
and was thus avoided.
Our overall interpretation of the data suggests that there is direct correlation between the
number of treatments to which an animal was exposed and the emergence of treatment resistance
in samples submitted to a veterinary diagnostic laboratory for analysis. In addition, sequential
treatments of BRD and the use of antimicrobials with different mechanisms of antibacterial activ-
ity (i.e., -static versus -cidal) may serve as a risk factor for the development of AMR.
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